ProCE Banner Activity

LIBERTY AD PEDS Study Results: Efficacy and Safety of Dupilumab in Children Aged ≥ 6 to < 12 Yrs With Severe Atopic Dermatitis

Slideset Download
Conference Coverage
Severe atopic dermatitis was significantly improved for children aged ≥ 6 to < 12 years with dupilumab vs placebo. 

Released: July 20, 2020

Expiration: July 19, 2021

No longer available for credit.

Share

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

This educational activity is supported by educational grants from

AbbVie Inc.

Pfizer, Inc.